-DOCSTART- -X- O
Human -X- _ B-Patient
immunodeficiency -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HIV -X- _ I-Patient
) -X- _ I-Patient
types -X- _ I-Patient
1 -X- _ I-Patient
and -X- _ I-Patient
2 -X- _ I-Patient
( -X- _ I-Patient
HIV-1 -X- _ I-Patient
and -X- _ I-Patient
HIV-2 -X- _ I-Patient
) -X- _ I-Patient
are -X- _ O
the -X- _ O
etiologic -X- _ O
agents -X- _ O
of -X- _ O
AIDS. -X- _ O
Most -X- _ O
HIV-1 -X- _ B-Patient
infected -X- _ I-Patient
individuals -X- _ I-Patient
worldwide -X- _ O
are -X- _ O
women -X- _ O
, -X- _ O
who -X- _ O
acquire -X- _ O
HIV -X- _ O
infections -X- _ O
during -X- _ O
sexual -X- _ O
contact. -X- _ O
Blocking -X- _ O
HIV -X- _ O
mucosal -X- _ O
transmission -X- _ O
and -X- _ O
local -X- _ O
spread -X- _ O
in -X- _ O
the -X- _ O
female -X- _ O
lower -X- _ O
genital -X- _ O
tract -X- _ O
is -X- _ O
important -X- _ O
in -X- _ O
preventing -X- _ O
infection -X- _ O
and -X- _ O
ultimately -X- _ O
eliminating -X- _ O
the -X- _ O
pandemic. -X- _ O
Microbicides -X- _ O
work -X- _ O
by -X- _ O
destroying -X- _ O
the -X- _ O
microbes -X- _ O
or -X- _ O
preventing -X- _ O
them -X- _ O
from -X- _ O
establishing -X- _ O
an -X- _ O
infection. -X- _ O
Thus -X- _ O
, -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
different -X- _ O
types -X- _ O
of -X- _ O
microbicides -X- _ O
are -X- _ O
under -X- _ O
investigation -X- _ O
, -X- _ O
however -X- _ O
, -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
their -X- _ O
solubility -X- _ O
and -X- _ O
bioavailability -X- _ O
, -X- _ O
and -X- _ O
toxicity -X- _ O
has -X- _ O
been -X- _ O
major -X- _ O
hurdles. -X- _ O
Herein -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
multifunctional -X- _ B-Intervention
chitosan-lipid -X- _ I-Intervention
nanocomplexes -X- _ I-Intervention
that -X- _ O
can -X- _ O
effectively -X- _ B-Outcome
deliver -X- _ I-Outcome
plasmids -X- _ I-Outcome
encoding -X- _ I-Outcome
siRNA -X- _ I-Outcome
( -X- _ I-Outcome
s -X- _ I-Outcome
) -X- _ I-Outcome
as -X- _ I-Outcome
microbicides -X- _ I-Outcome
without -X- _ I-Outcome
adverse -X- _ I-Outcome
effects -X- _ I-Outcome
and -X- _ I-Outcome
provide -X- _ I-Outcome
significant -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
HIV -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
models. -X- _ I-Outcome
Chitosan -X- _ B-Intervention
or -X- _ I-Intervention
chitosan-lipid -X- _ I-Intervention
( -X- _ I-Intervention
chlipid -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ I-Intervention
complexed -X- _ I-Intervention
with -X- _ I-Intervention
a -X- _ I-Intervention
cocktail -X- _ I-Intervention
of -X- _ I-Intervention
plasmids -X- _ I-Intervention
encoding -X- _ I-Intervention
HIV-1-specific -X- _ I-Intervention
siRNAs -X- _ I-Intervention
( -X- _ I-Intervention
psiRNAs -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
evaluated -X- _ O
for -X- _ O
their -X- _ O
efficacy -X- _ O
in -X- _ O
HEK-293 -X- _ B-Comparison
cells -X- _ I-Comparison
, -X- _ I-Comparison
PBMCs -X- _ I-Comparison
derived -X- _ I-Comparison
from -X- _ I-Comparison
nonhuman -X- _ I-Comparison
primates -X- _ I-Comparison
, -X- _ I-Comparison
3-dimensional -X- _ I-Comparison
human -X- _ I-Comparison
vaginal -X- _ I-Comparison
ectocervical -X- _ I-Comparison
tissue -X- _ I-Comparison
( -X- _ I-Comparison
3D-VEC -X- _ I-Comparison
) -X- _ I-Comparison
model -X- _ I-Comparison
and -X- _ I-Comparison
also -X- _ I-Comparison
in -X- _ I-Comparison
non-human -X- _ I-Comparison
primate -X- _ I-Comparison
model. -X- _ I-Comparison
Moreover -X- _ O
, -X- _ O
prophylactic -X- _ B-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
chlipid -X- _ I-Outcome
to -X- _ I-Outcome
deliver -X- _ I-Outcome
a -X- _ I-Outcome
psiRNA -X- _ I-Outcome
cocktail -X- _ I-Outcome
intravaginally -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
cream -X- _ I-Outcome
formulation -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
non-human -X- _ I-Outcome
primate -X- _ I-Outcome
model -X- _ I-Outcome
showed -X- _ I-Outcome
substantial -X- _ I-Outcome
reduction -X- _ I-Outcome
of -X- _ I-Outcome
SHIV -X- _ I-Outcome
( -X- _ I-Outcome
simian -X- _ I-Outcome
/ -X- _ I-Outcome
human -X- _ I-Outcome
immunodeficiency -X- _ I-Outcome
virus -X- _ I-Outcome
SF162 -X- _ I-Outcome
) -X- _ I-Outcome
viral -X- _ I-Outcome
titers. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
these -X- _ O
studies -X- _ O
demonstrate -X- _ O
the -X- _ O
potential -X- _ O
of -X- _ O
chlipid-siRNA -X- _ O
nanocomplexes -X- _ O
as -X- _ O
a -X- _ O
potential -X- _ O
genetic -X- _ O
microbicide -X- _ O
against -X- _ O
HIV -X- _ O
infections -X- _ O
. -X- _ O

